Status:
RECRUITING
Novel Therapeutic Approach for Human T-cell Malignancies
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Collaborating Sponsors:
Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale
Conditions:
T-Cell Leukemia/Lymphoma, Adult
Eligibility:
All Genders
18+ years
Brief Summary
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. I...
Eligibility Criteria
Inclusion
- Patients with pre- and post-thymic T-cell leukemia/lymphoma
- Patients of both sexes
- Age of patients older than 18 years
- Patient is willing to provide written and signed informed consent for participation in the study
Exclusion
- Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.
Key Trial Info
Start Date :
July 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06600568
Start Date
July 1 2024
End Date
July 1 2026
Last Update
December 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Nazionale Tumori Fondazione G.Pascale
Napoli, Italy, 80100
2
Istituto Oncologico Veneto
Padua, Italy, 35128